Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
|
526 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.700 | 1.000 | 1 | 2009 | 2009 | |||||
AIDS, PROGRESSION TO
|
526 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.700 | 1.000 | 1 | 2009 | 2009 | |||||
HIV-1, RESISTANCE TO
|
526 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.700 | 1.000 | 1 | 2009 | 2009 | |||||
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO
|
527 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.700 | 1.000 | 1 | 2009 | 2009 | |||||
Liver carcinoma
|
942 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.900 | 1.000 | 20 | 2011 | 2019 | |||||
Hepatitis C
|
347 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.100 | 1.000 | 10 | 2012 | 2019 | |||||
Liver Cirrhosis
|
189 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.030 | 0.667 | 3 | 2013 | 2018 | |||||
Hepatitis B
|
519 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.020 | 1.000 | 2 | 2013 | 2019 | |||||
Cirrhosis
|
110 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.010 | 1 | 2013 | 2013 | ||||||
Hepatitis B Virus-Related Hepatocellular Carcinoma
|
8 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Hepatitis B, Chronic
|
84 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Fibrosis, Liver
|
64 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Hepatitis C Virus-Related Hepatocellular Carcinoma
|
1 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Liver diseases
|
100 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Neoplasms
|
1644 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Hepatitis C, Chronic
|
80 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.020 | 1.000 | 2 | 2019 | 2019 | |||||
Hepatocarcinogenesis
|
24 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.020 | 1.000 | 2 | 2019 | 2019 | |||||
Pseudohyperkalemia Cardiff
|
60 | 0.724 | 0.200 | 6 | 31398818 | upstream gene variant | C/T | snv | 0.41 | 0.010 | 1.000 | 1 | 2019 | 2019 |